The call for abstracts is open and runs until 1 April 2026. 

1.  All submissions should be made in English and only through the online submission platform.  Abstracts submitted in a language other than English will be automatically rejected.
2. The abstract must contain at least 1,500 characters and cannot contain more than 3,000 characters (blank spaces, punctuation as well as authors’ affiliation and titles included).
3. A prescribed format has been identified for each type of submission format:

• Scientific studies. Background, aim, methods, results, conclusions.
• Practice, policy and advocacy reports. Background and context, aim, strategy/tactics, programme/policy process, outcomes, what was learned (develop any replicability potential)
• Fundraising campaign reports. Amount raised, background and context, aim, strategy/tactics, programme process, stakeholders involved, costs and returns, innovative methods, what was learned. Mention any replicability potential.
   

4. Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are possible after the submission. The abstract will be reproduced exactly as submitted. Please ensure that the abstract is complete. No proofreading will be done.
5. Work reported in abstracts should meet international ethical standards.
6. Abbreviations should be defined.
7. All graphics and supporting visuals need to be commented upon and have an explanatory title.
8. The submitting author accepts to declare all of the authors’ conflicts of interest for the last 5 years. An abstract or summary report cannot be accepted if the conflict-of-interest disclosure has not been ticked on the submission form. If the project or one of the co-authors has a conflict of interest, this must be clearly stated within the submission form and then, later, upon acceptance of the abstract, disclosed within the presentation.
9. Each author needs to have authorized the submitter to submit the abstract, and then, later, upon acceptance of the abstract, approve its presentation at the Congress. The submission system will require co-authors’ details to notify them of the abstract submission.
10. By submitting your abstract, you acknowledge that its content may be publicly disseminated, including media reporting. The UICC communications team may contact authors of abstracts with strong media potential to confirm availability for press materials or briefings, and authors should discuss any permissions or embargoes with relevant journals or institutions in advance. Please note that inability to discuss findings beyond the abstract may limit media coverage.
11. Please ensure that all sources of information and references are included.
12. Once you have successfully submitted your abstract, you will receive a confirmation email with an abstract ID number to use in any communication you might have with the organisers.
13. Abstracts can be re-edited and modified until you click “submit” for final submission. Once submitted, abstracts cannot be edited.
14. All abstracts should be finalised and submitted by 1 April 2026 at 23:59 CET.
15. As a result of the abstract review phase, by 12 May 2026, all submitters will receive a notification of their presentation format.
16. By 3 July 2026, all accepted abstracts will have to either:

• register to attend the Congress in person, if selected for an in-person presentation at the World Cancer Congress in Hong Kong. An in-person registration also includes the opportunity for the author to have the abstract displayed as an e-Poster in the eLibrary on the online platform; or
• purchase a digital pass for the online platform if the accepted abstract is to feature in the abstract eLibrary only.

A presenter that has not registered or purchased a digital pass by 3 July will have their abstract withdrawn from the programme and the abstract eLibrary.